Latest Articles

Publication Date
Management of Endometriosis-Related Pain: Comparing the Effectiveness of Hormonal Therapy, Surgical Interventions, and Complementary Therapies - Cureus

Management of Endometriosis-Related Pain: Comparing the Effectiveness of Hormonal Therapy, Surgical Interventions, and Complementary Therapies Cureus

Published: Dec. 12, 2024, 2:19 p.m.
Catamenial Pneumothorax in a Patient Undergoing Low-Dose Estrogen-Progestin Therapy: A Case Report - Cureus

Catamenial Pneumothorax in a Patient Undergoing Low-Dose Estrogen-Progestin Therapy: A Case Report Cureus

Published: Dec. 11, 2024, 1:59 p.m.
Top Gynecologic Cancer Research of 2024 - Cancer Therapy Advisor

Top Gynecologic Cancer Research of 2024 Cancer Therapy Advisor

Published: Dec. 9, 2024, 3 p.m.
Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer - OncLive

Immunotherapy Redefines Standard of Care for Frontline Advanced Endometrial Cancer OncLive

Published: Dec. 5, 2024, 7:04 p.m.
NMPA greenlights new endometrial cancer therapy - Investing.com India

NMPA greenlights new endometrial cancer therapy Investing.com India

Published: Dec. 4, 2024, 1:01 a.m.
Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | IVBIY Stock News - StockTitan

Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | IVBIY Stock News StockTitan

Published: Dec. 4, 2024, 12:01 a.m.
Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | HCM Stock News - StockTitan

Innovent & HUTCHMED Win China Approval for Breakthrough Endometrial Cancer Therapy | HCM Stock News StockTitan

Published: Dec. 4, 2024, midnight
Elagolix with add-back therapy found effective and tolerable for endometriosis pain - Contemporary Obgyn

Elagolix with add-back therapy found effective and tolerable for endometriosis pain Contemporary Obgyn

Published: Dec. 3, 2024, 6:36 p.m.
NMPA greenlights new endometrial cancer therapy By Investing.com - Investing.com Australia

NMPA greenlights new endometrial cancer therapy By Investing.com Investing.com Australia

Published: Dec. 3, 2024, 10:15 a.m.
Study identifies key risk factors for recurrence in early endometrial cancer after hormonal therapy - KBR

Study identifies key risk factors for recurrence in early endometrial cancer after hormonal therapy KBR

Published: Dec. 3, 2024, 6:49 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!